Document:

<PAGE>   1
                                                                  EXHIBIT 10.13

            AMENDED AND RESTATED LICENSE AND CROSS-LICENSE AGREEMENT

         This Amended and Agreement is made on this 27th day of July, 2000
between MOTOROLA, INC. ("MOTOROLA"), a corporation of the State of Delaware,
having its principal place of business at 1301 East Algonquin Road, Schaumburg,
Illinois 60196, and GMP|WIRELESS MEDICINE, INC., (hereinafter the "LICENSEE"),
a Delaware corporation, having its principal place of business at One East
Broward Blvd., Ft. Lauderdale, Florida 33301.

                                  WITNESSETH:

         WHEREAS, MOTOROLA possesses certain PATENT RIGHTS (hereinafter
defined) in wireless medical devices and related technologies that it is
interested in having manufactured, marketed, distributed and sold to hospitals,
healthcare provider offices, and acute, subacute and chronic medical outpatient
facilities throughout the world; and

         WHEREAS, LICENSEE desires to manufacture, market, distribute and sell
such devices to hospitals, healthcare provider offices, and acute, subacute and
chronic medical outpatient facilities throughout the world; and

         WHEREAS, MOTOROLA has acquired through assignment all rights, title
and interest, in said PATENT RIGHTS; and

         WHEREAS, MOTOROLA and LICENSEE will be involved with research and
development directed to improvements to said PATENT RIGHTS and MOTOROLA and
LICENSEE desire to cross-license and market the improvements; and

         WHEREAS, the parties hereto have previously entered into a certain
License and Cross License Agreement dated May 11, 2000 (the "LICENSE
AGREEMENT") pertaining to said PATENT RIGHTS and wish to make certain
modifications and amendments to the same.

         NOW, THEREFORE, in exchange for the consideration set forth herein,
and other good and valuable consideration, the receipt of which is hereby
acknowledged, and intending to be legally bound hereby, the parties agree to
modify and amend the LICENSE AGREEMENT in accordance with the following amended
and restated terms of said LICENSE AGREEMENT as follows:

                                       1
<PAGE>   2

                            ARTICLE 1 - DEFINITIONS

         1.1      "AFFILIATED COMPANY" OR "AFFILIATED COMPANIES" shall mean any
corporation, company, partnership, joint venture or other entity which
controls, is controlled by or is under common control with the LICENSEE. For
purposes of this Paragraph, control shall mean the direct or indirect ownership
of at least fifty percent (50%) of the voting securities of the controlled
entity.

         1.2      "DEVELOPMENT AGREEMENT" shall mean the Research and
Development agreement of even date between MOTOROLA and LICENSEE, a copy of
which is attached hereto as Exhibit A, covering the development of wireless EKG
products, including the Working Prototype and other wireless sensor
technologies such as vital sign and pulse oximetry but excluding glucose
monitoring.

         1.3      "DISTRIBUTION REVENUES" shall mean gross margins (defined as
sales price minus manufacturing costs (or purchase price, if LICENSEE chooses
to have LICENSED PRODUCTS manufactured on its behalf, all in accordance with US
generally accepted accounting procedures) derived by LICENSEE or AFFILIATED
COMPANIES from their sale, lease or use of LICENSED PRODUCT(S) to a distributor
for resale or lease to or use by end users, less trade discounts allowed,
refunds, returns and recalls, sales taxes, freight, storage and delivery costs,
discounts or rebates accrued, incurred or paid to Federal Medicaid or State
Medicare or other payors, amounts exactly repaid or credited by reason of
rejections or the return of LICENSED PRODUCTS (due to recalls, dating or other
reasons), and any other reasonable and customary deductions that according to
generally accepted accounting principles are bona fide deductions from gross
sales to determine DISTRIBUTION REVENUES. DISTRIBUTION REVENUES do not include
any monies received by LICENSEE or AFFILIATED COMPANIES from SUBLICENSEES.

         1.4      "EFFECTIVE DATE" shall mean the later of July 27, 2000.

         1.5      "EXCLUDED FIELD" shall mean any field other than the LICENSED
FIELD.

         1.6      "EXECUTION DATE" shall mean May 11, 2000.

         1.7      "EXCLUSIVE RIGHT" shall mean a grant by MOTOROLA to LICENSEE
of its entire right and interest in the PATENT RIGHTS to make, have made, offer
for sale, sell, use,

                                       2
<PAGE>   3

import, market, have sold, develop, distribute and otherwise commercially
exploit LICENSED PRODUCTS throughout the world in the LICENSED FIELD. By this
grant it is intended that MOTOROLA shall not have the right to enter the
LICENSED FIELD.

         1.8      "KNOW-HOW" means all business, scientific, technical or any
other knowledge related to the design, commercialization, manufacture, use and
implementation of the PATENT RIGHTS and which is previously or subsequently
created or acquired by MOTOROLA during the term of this Agreement.

         1.9      "LICENSED FIELD" shall mean any and all uses of LICENSED
PRODUCT(S) in hospitals; healthcare provider offices; acute, subacute and
chronic medical outpatient facilities; and other health and medical related
facilities. Any other uses by LICENSEE must be approved in writing by MOTOROLA.
To the extent otherwise consistent with the terms of this Agreement, LICENSEE
agrees to use reasonable efforts to cooperate with MOTOROLA in insuring
compliance by its customers with respect to the use of LICENSED PRODUCTS solely
in the LICENSED FIELD, including if necessary discontinuing sale to customers
using the product outside the LICENSED FIELD. In such circumstances, unless
LICENSEE has taken affirmative actions to facilitate a third party's use
outside of the LICENSED FIELD, MOTOROLA agrees to take no action that would
impose liability or obligations on LICENSEE for third party use of a LICENSED
PRODUCT outside of the LICENSED FIELD.

         1.10     "LICENSED PRODUCT(S)" means any device, product, system or
method that is covered by any VALID CLAIM of any patent that is defined in the
PATENT RIGHTS (coverage by a claim shall include, but is not limited to, direct
infringement, contributory infringement, or inducement to infringe).

         1.11     "NET SALES" shall mean gross revenues received by LICENSEE or
AFFILIATED COMPANIES from their direct sale, lease or use of LICENSED
PRODUCT(S) to or for end users, less trade discounts allowed, refunds, returns
and recalls, sales taxes, freight, storage and delivery costs, sales taxes,
discounts or rebates accrued, incurred or paid to Federal Medicaid or State
Medicare or other payors, amounts exactly repaid or credited by reason of
rejections or the return of LICENSED PRODUCTS (due to recalls, dating or other
reasons), and any other reasonable and customary deductions that according to
generally accepted accounting principles are bona fide deductions from gross
sales to determine NET SALES. NET SALES do

                                       3
<PAGE>   4

not include any monies received by LICENSEE or AFFILIATED COMPANIES from
SUBLICENSEES.

         1.12     "PATENT RIGHTS" means:

                  (a) the United States, international and foreign patents
listed on Appendix A as of the date hereof and any additions to the PATENT
RIGHTS which are the result of modifications to or improvements in the
technology or design employed in LICENSED PRODUCTS used within the LICENSED
FIELD;

                  (b) any patents which issue from the United States,
international and foreign patent applications converted from provisional
applications listed on Appendix A and any issued patents that claim priority to
said applications;

                  (c) any divisionals, continuations, continuation-in-part
applications, and/or continued prosecution applications (and their relevant
international or foreign equivalents) of the patent applications listed on
Appendix A;

                  (d) any patents resulting from reissues, reexaminations, or
extensions (and their relevant international equivalents) of the patents
described in (a), (b), and/or (c) above; and.

                  (e) any MOTOROLA FUTURE PATENT RIGHTS, as such term is
defined in Article 9 below.

         1.13     "SUBLICENSE REVENUES" shall mean revenue received by the
LICENSEE or AFFILIATED COMPANIES from a sublicensee for the sale, lease or use
of LICENSED PRODUCTS by, through or under the SUBLICENSEE.

         1.14     "TERM" shall mean the expiration date of the latest expiring
patent that is identified in the PATENT RIGHTS.

         1.15     "TERRITORY" shall mean the world.

         1.16     "VALID CLAIM" shall mean any claim of an issued and unexpired
patent that is identified in the PATENT RIGHTS, which has not been held
unpatentable, invalid or unenforceable by a court or other government agency of
competent jurisdiction and has not been admitted to be invalid or unenforceable
through reissue, re-examination, disclaimer or otherwise; provided, however,
that if the holding of such court or agency is later reversed by a court or
agency with overriding authority, the claim shall be reinstated as a VALID
CLAIM after the date of such reversal.

                                       4
<PAGE>   5

         1.17     "WORKING PROTOTYPE" means LICENSED PRODUCTS consisting of a
sensor, transmitter unit and a receiver or base unit for a wireless EKG
machine, the specifics of which will be developed under the DEVELOPMENT
AGREEMENT.

                               ARTICLE 2 - GRANTS

2.       Subject to the terms and conditions of this Agreement, MOTOROLA hereby
grants to the LICENSEE:

         2.1      the EXCLUSIVE RIGHTS in the LICENSED FIELD under the PATENT
RIGHTS and KNOW-HOW in the TERRITORY for the TERM;

         2.2      the right to sublicense the rights granted under subsection
2.1 above to others, except that LICENSEE shall not have the right to
sublicense its rights under this Agreement to any of Abbott Laboratories, Inc.,
Baxter Corporation, Johnson & Johnson, Inc., Hewlett-Packard Corp., Agilent
Corp., GE Medical Systems, Inc., MiniMed, Inc. or Siemens Corp. without the
prior written consent of MOTOROLA, which consent shall not be unreasonably
withheld, LICENSEE agrees to provide a copy of each such sublicense agreement
to MOTOROLA promptly after it is executed; and

         2.3      the right of first refusal to make, use, sell and import
LICENSED PRODUCTS for the EXCLUDED FIELD, if MOTOROLA decides to grant any such
rights to third parties; which right shall permit LICENSEE to obtain an
exclusive license for the same upon terms no less favorable than that offered
or given to any third parties.

                    ARTICLE 3 - PAYMENTS, ROYALTY AND EQUITY

         3.1      The LICENSEE shall pay to MOTOROLA an initial licensing fee
of One Million Dollars ($1,000,000) upon the EFFECTIVE DATE of this Agreement.
This fee is non-refundable and shall not be credited towards any royalty or
other payment due under this Agreement.

         3.2      The LICENSEE shall pay to MOTOROLA a licensing fee of One
Million Dollars ($1,000,000) within thirty (30) days of the delivery to
LICENSEE of WORKING PROTOTYPES by MOTOROLA that are suitable for submission to
the U.S. Food and Drug Administration ("FDA") and the Federal Communication
Commission ("FCC") in connection with receiving approval to sell

                                       5
<PAGE>   6

such LICENSED PRODUCTS. This fee is non-refundable and shall not be credited
towards any royalty or other payment due under this Agreement.

         3.3      The LICENSEE shall pay to MOTOROLA a licensing fee of One
Million Dollars ($1,000,000) within thirty (30) days of LICENSEE receiving
regulatory approval for the WORKING PROTOTYPES from the FDA and FCC (the
"APPROVAL DATE"). This fee is non-refundable and shall not be credited towards
any royalty or other payment due under this Agreement.

         3.4      The LICENSEE shall pay to MOTOROLA a licensing fee of One
Million Five Hundred Thousand Dollars ($1,500,000) either one (1) year after
the EFFECTIVE DATE or six (6) months after the APPROVAL DATE, whichever is
earlier. This fee is non-refundable and shall not be credited towards any
royalty or other payment due under this Agreement.

         3.5      The LICENSEE shall pay to MOTOROLA Running Royalties of Two
Percent (2%) of current NET SALES where the aggregate of NET SALES over the
life of this Agreement is less than Twenty-five Million Dollars ($25,000,000).
For aggregate NET SALES over the life of this Agreement greater than Twenty-
Five Million Dollars ($25,000,000) but less than Fifty Million Dollars
($50,000,000), the Running Royalties due from LICENSEE shall be two and
one-half percent (2.5%) of such NET SALES. For aggregate NET SALES over the
life of the Agreement greater than Fifty Million Dollars ($50,000,000), the
Running Royalty due from LICENSEE shall be three percent (3%) of such NET
SALES.

         3.6      The LICENSEE shall pay to MOTOROLA a royalty of twenty
percent (20%) of any and all payments received by LICENSEE constituting
DISTRIBUTION REVENUES.

         3.7      In the event LICENSEE has granted sublicenses under this
Agreement, LICENSEE shall pay a Royalty to MOTOROLA the greater of: (1) twenty
percent (20%) of any and all payments received by LICENSEE from SUBLICENSE
REVENUES; or (2) one half (1/2) of the amount that MOTOROLA would have received
if such sale had been made directly by LICENSEE.

         3.8      The LICENSEE shall provide to MOTOROLA within forty-five (45)
days of the end of each March, June, September and December after the APPROVAL
DATE of this Agreement, a written report containing the amount of LICENSED
PRODUCTS sold by the LICENSEE and AFFILIATED COMPANIES, the total associated
NET SALES, DISTRIBUTION REVENUES and SUBLICENSE REVENUES and the running
royalties due to MOTOROLA as a result of NET SALES, DISTRIBUTION REVENUES and
SUBLICENSE REVENUES for the applicable calendar

                                       6
<PAGE>   7

quarter. Payment of any such royalties due shall accompany such report.

         In the event that any payment due hereunder is not made when due, the
payment shall accrue interest beginning on the tenth day following the due date
thereof, calculated at the annual rate of the sum of two percent (2%) plus the
prime interest rate quoted by The Wall Street Journal on the date said payment
is due, the interest being compounded on the last day of each calendar quarter;
provided, however, that in no event shall said annual interest rate exceed the
maximum legal interest rate for corporations. Each such royalty payment when
made shall be accompanied by all interest so accrued. Said interest and the
payment and acceptance thereof shall not negate or waive the right of MOTOROLA
to seek any other remedy, legal or equitable, to which it may be entitled under
this Agreement because of the delinquency of any payment.

         3.9      The LICENSEE shall make and retain, for a period of three (3)
years following the period of each report required by Paragraph 3.8, true and
accurate records, files and books of account containing all the data reasonably
required for the full computation and verification of sales and other
information required in Paragraph 3.8. Such books and records shall be in
accordance with generally accepted accounting principles consistently applied.
The LICENSEE shall permit the inspection and copying of such records, files and
books of account by MOTOROLA or its agents during regular business hours upon
ten (10) business days' written notice to the LICENSEE. Such inspection shall
not be made more than once each calendar year. All costs of such inspection and
copying shall be paid by MOTOROLA, provided that if any such inspection shall
reveal that an error has been made in the amount equal to ten percent (10%) or
more of such payment, reasonable costs for such inspection and copying shall be
borne by the LICENSEE. The LICENSEE shall include in any agreement with its
AFFILIATED COMPANIES or its sublicensees that permits such party to make, use
or sell the LICENSED PRODUCT(S), a provision requiring such party to retain
records of sales of LICENSED PRODUCT(S) and other information as required in
Paragraph 3.8 and permit MOTOROLA to inspect such records as required by this
Paragraph.

         3.10     No royalties shall be payable on LICENSED PRODUCT sales,
sublicenses or other transactions between the LICENSEE and any AFFILIATED
COMPANIES, in which event the royalty shall be based upon the NET SALES,
DISTRIBUTION REVENUES or SUBLICENSE REVENUES of the AFFILIATED COMPANY.

                                       7
<PAGE>   8

         3.11     No multiple royalties shall be due and payable because any
LICENSED PRODUCT is covered by more than one patent that is within the
definition of PATENT RIGHTS.

         3.12     MOTOROLA agrees that no royalties shall be due for the
internal use of the LICENSED PRODUCTS for research and commercial development
purposes by the LICENSEE and AFFILIATED COMPANIES or for use by third parties
providing research and development activities on behalf of the LICENSEE or
AFFILIATED COMPANIES in seeking governmental and professional approvals,
certifications or endorsements, or for training purposes, except where the
LICENSEE or any AFFILIATED COMPANY receives revenues for the sale, lease or use
of the LICENSED PRODUCT from the organization using the device for such stated
proposes.

         3.13     To the extent that LICENSEE incurs costs in connection with
any alleged infringement of third party patents and/or obtains, subsequent to
the EXECUTION DATE, licenses to third party patents or other intellectual
property that are necessary to make, use, import or sell LICENSED PRODUCTS with
the same functionality as: (a) the Working Prototype, or (b) otherwise covered
by a PATENT RIGHT as the same existed on the EFFECTIVE DATE, LICENSEE may
deduct from the royalties due to MOTOROLA fifty percent (50%) of the costs
incurred and/or royalties due on such third party patents or intellectual
property up to an amount equal to fifty percent (50%) of royalties due
hereunder. The royalty deductions described in this Paragraph 13 shall not
apply to any third party licenses that encompass aesthetic changes or
additional product functionality.

         3.14     For purposes of calculating royalties, in the event that a
LICENSED PRODUCT includes both component(s) covered by a VALID CLAIM of a
PATENT RIGHT ("Patented Component") and component(s) that are useful alone or
in a combination which does not require the Patented Component, and such
components are not covered by a VALID CLAIM of a PATENT RIGHT ("Unpatented
Component"), then NET SALES, DISTRIBUTION REVENUES or SUBLICENSE REVENUES of
the Combination Product shall be calculated using one of the following methods:

                  (a)      By multiplying the NET SALES, DISTRIBUTION REVENUES
                  or SUBLICENSE REVENUES of the Combination Product during the
                  applicable royalty accounting period ("accounting period") by
                  a fraction, the numerator of which is the aggregate gross
                  selling price of the Patented Component(s) contained in the

                                       8
<PAGE>   9

                  Combination Product if sold separately, and the denominator
                  of which is the sum of the gross selling price of both the
                  Patented Component(s) and the Unpatented Component(s)
                  contained in the Combination Product, if sold separately; or

                  (b)      In the event that no such separate sales are made of
                  the Patented Component(s) or the Unpatented Components during
                  the applicable accounting period, NET SALES, DISTRIBUTION
                  REVENUES or SUBLICENSE REVENUES for purposes of determining
                  royalties payable hereunder shall be calculated by
                  multiplying the NET SALES, DISTRIBUTION REVENUES or
                  SUBLICENSE REVENUES, as applicable, of the Combination
                  Product by a fraction, the numerator of which is the fully
                  allocated production cost of the Patented Component(s) and
                  the denominator of which is the sum of the fully allocated
                  production costs of the Patented Component(s) and the
                  Unpatented Component(s) contained in the Combination Product.
                  Such fully allocated costs shall be determined by using
                  LICENSEE's standard accounting procedures, which procedures
                  must conform to standard cost accounting procedures.

                  (c)      For purposes of Subparagraphs (a) or (b) above,
                  Patented Components shall include any LICENSED PRODUCTS that
                  have the functional equivalent of any Unpatented Component
                  and the Unpatented Component shall not include any such
                  functionally equivalent device.

         3.15     LICENSEE agrees to fund no less than Six Million Dollars
($6,000,000) for research and development under the DEVELOPMENT AGREEMENT
between LICENSEE and MOTOROLA. Such funds will be paid pursuant to the payment
terms set forth in the DEVELOPMENT AGREEMENT. Any inventions or discoveries
conceived or first reduced to practice in the performance of activities under
the DEVELOPMENT AGREEMENT shall be owned and cross-licensed as detailed below.

                          ARTICLE 4 - OTHER AGREEMENTS

         4.1      The LICENSEE shall issue to MOTOROLA upon the EFFECTIVE DATE
One Million Five Hundred Thousand (1,500,000) shares of LICENSEE'S common stock
pursuant to the

                                       9
<PAGE>   10

Stock Acquisition Agreement to be dated the EFFECTIVE DATE between MOROROLA and
the LICENSEE, a copy of which is attached hereto as Exhibit B.

         4.2      MOTOROLA, LICENSEE and GMP|Companies, Inc. ("GMP") agree to
enter into that certain Shareholders Agreement on the EFFECTIVE DATE, a copy of
which is attached hereto as Exhibit C.

         4.3      From and after the EFFECTIVE DATE of this Agreement, MOTOROLA
agrees to provide to LICENSEE, from time to time, and as requested by LICENSEE,
copies of all tangible materials representing KNOW-HOW, including without
limitation, reports, studies, diagrams, designs, bills of material, business
plans, test data, manufacturing data, and specifications. MOTOROLA also agrees
to cause appropriate representatives of MOTOROLA to confer with LICENSEE and
its sublicensees with respect to technical matters related to LICENSED PRODUCTS
and the manufacture, design, use and regulatory approvals of the same.

         4.4      MOTOROLA shall have the right of first refusal to bid to be
the supplier of LICENSED PRODUCTS where the LICENSEE or a sublicensee elects to
have third parties manufacture such products for commercial purposes in such
quantities and/or periods of time as specified by the LICENSEE or a
sublicensee. For purposes of this Agreement, the parties intend to implement
the right of first refusal as follows: If LICENSEE or sublicensee elects to
have third parties manufacture LICENSED PRODUCTS for commercial purposes, it
shall provide MOTOROLA with a request for proposal for such manufacture, which
proposal shall include specifications, terms and conditions as may be
reasonably requested by LICENSEE or a sublicensee. Such proposal shall be
submitted by MOTOROLA to the LICENSEE or sublicensee within 20 business days
from the date of receipt of the request from the LICENSEE or sublicensee or
such later date specified in the request. The LICENSEE or sublicensee shall
then be allowed to seek other bids from third parties, provided that MOTOROLA
shall have the right to match any such bid. If the LICENSEE or a sublicensee
receives a bid from another manufacture which the LICENSEE or a sublicensee
wishes to pursue, the LICENSEE or sublicensee shall provide Motorola notice of
such proposal, and MOTOROLA shall have the right to match such proposal.

         4.5      The parties agree to actively promote the relationship of the
parties with respect to the subject matter of this Agreement, including,
without limitation, co-branding the LICENSED PRODUCTS with MOTOROLA'S and
LICENSEE'S names, in a form to be mutually agreed upon

                                      10
<PAGE>   11

by the parties.

         4.6      Except as otherwise provided by this Agreement, LICENSEE
shall not use MOTOROLA's name nor the name of any of its corporate affiliates
or employees, nor any adaptation thereof, in any advertising, promotional or
sales literature without prior written consent obtained from MOTOROLA in each
case, except that LICENSEE must state that it is licensed by MOTOROLA under one
or more of the patents comprising the PATENT RIGHTS, that the LICENSED PRODUCTS
are developed in cooperation with MOTOROLA, and LICENSEE may comply with
disclosure requirements of all applicable laws relating to its business,
including United States and State securities laws as determined by LICENSEE's
counsel. Any consent required hereunder shall not be unreasonably withheld or
delayed by MOTOROLA.

             ARTICLE 5 - PATENT RIGHTS AND CONFIDENTIAL INFORMATION

         5.1      MOTOROLA shall, at its cost, file, prosecute and maintain all
patents and patent applications specified under PATENT RIGHTS in the United
States, Europe, Japan, Mexico and Australia, together with such other
jurisdictions as reasonable requested by LICENSEE. LICENSEE shall be copied
directly on all patent correspondence, provided copies of all correspondence
received from any patent office and provided drafts of any papers or
applications to be filed at least two weeks prior to patent office submission
or as promptly as practicable for comment. LICENSEE's comments shall be
considered and reasonably incorporated and LICENSEE agrees to reasonably and
promptly cooperate in the execution and delivery of documentation required in
connection with such matters and Licensee shall take all reasonable steps to
ensure its participation in these processes meet whatever filing deadlines may
be required. In any country where MOTOROLA elects not to file a patent
application or to pay expenses associated with filing, prosecuting, or
maintaining a patent application or patent, MOTOROLA shall notify LICENSEE of
its election a reasonable amount of time prior to the deadline for filing,
prosecuting or maintaining any applications in said country. LICENSEE
thereafter may file, prosecute, and/or maintain a patent application or patent
at its own expense and for its own exclusive benefit in said country and
LICENSEE thereafter shall not be required to pay any royalties, NET SALES or
SUBLICENSE REVENUES to MOTOROLA for

                                      11
<PAGE>   12

products covered by such patent or patent application in the applicable
country.

         5.2      LICENSEE agrees that any and all individual LICENSED
PRODUCT(S) sold, used or leased by LICENSEE, AFFILIATED COMPANIES and
sublicensees will be marked with the number of the applicable patent(s)
licensed hereunder in accordance with each country's patent laws. If it is
impossible to mark the LICENSED PRODUCT directly, LICENSEE may mark the product
package.

         5.3      If necessary, the parties will exchange information, which
they consider to be confidential. The recipient of such information agrees to
accept the disclosure of said information which is marked as confidential at
the time it is sent to the recipient, and to employ all reasonable efforts to
maintain the information secret and confidential, such efforts to be no less
than the degree of care employed by the recipient to preserve and safeguard its
own confidential information. The information shall not be disclosed or
revealed by the recipient to anyone except employees and affiliates of the
recipient who have a need to know the information and who have entered into a
secrecy agreement with the recipient, under which such employees and affiliates
are required to maintain confidential the proprietary information of the
recipient and such employees and affiliates shall be advised by the recipient
of the confidential nature of the information and that the information shall be
treated accordingly. The recipient's obligations under this Paragraph shall not
extend to any part of the information:

                  (a)      that can be demonstrated to have been in the public
         domain or publicly known and readily available to the trade or the
         public prior to the date of the disclosure; or

                  (b)      that can be demonstrated, from written records to
         have been in the recipient's possession or readily available to the
         recipient from another source not under obligation of secrecy to the
         disclosing party prior to the disclosure; or

                  (c)      that becomes part of the public domain or publicly
         known by publication or otherwise, not due to any unauthorized act by
         the recipient; or

                  (d)      that is demonstrated from written records to have
         been developed by or for the receiving party without reference to
         confidential information disclosed by the disclosing party; or

                  (e)      that is required to be disclosed by law, government
         regulation or court order, as reasonably determined by counsel.

                                      12
<PAGE>   13

The obligations of this Paragraph shall also apply to AFFILIATED COMPANIES
and/or sublicensees provided such information by LICENSEE. MOTOROLA'S,
LICENSEE'S, AFFILIATED COMPANIES', and sublicensees' obligations under this
Paragraph shall extend until three (3) years after the termination of this
Agreement. Upon written request of the disclosing party, the other party shall
return or certify to the destruction of all copies of materials containing
confidential information of the disclosing party.

                        ARTICLE 6 - PATENT INFRINGEMENT

         6.1      Each party will notify the other promptly in writing when any
infringement by another of the PATENT RIGHTS in the LICENSED FIELD is uncovered
or suspected.

         6.2      MOTOROLA shall have the first right to enforce any patent
within PATENT RIGHTS in the LICENSED FIELD against any infringement or alleged
infringement, past or future, thereof, and shall at all times keep LICENSEE
informed as to the status thereof. MOTOROLA may, in its sole judgment and at
its own expense, institute suit against any such infringer or alleged infringer
and control, settle, and defend such suit in a manner consistent with the terms
and provisions hereof. Should any damages award or settlement obtained exceed
the costs of such action, the remaining portion shall be treated as NET SALES.
This right to sue for infringement shall not be used in an arbitrary or
capricious manner. LICENSEE shall reasonably cooperate in any such litigation.

         6.3      If MOTOROLA elects not to enforce any patent within the
PATENT RIGHTS in the LICENSED FIELD against any infringer, then it shall so
notify LICENSEE in writing within six (6) months of receiving notice that an
infringement may exist, or such other shorter period as may be reasonably
requested by LICENSEE, and LICENSEE may, in its sole judgment and at its own
expense, take steps to enforce any patent and control, settle, and defend such
suit in a manner consistent with the terms and provisions hereof. MOTOROLA
shall reasonably cooperate in any such litigation.

         6.4      Any recovery by LICENSEE under Paragraph 6.3 shall be deemed
to reflect loss of commercial sales, and LICENSEE shall pay to MOTOROLA the
same percent of the recovery net of

                                      13
<PAGE>   14

all reasonable costs and expenses associated with each suit or settlement as if
such net constituted NET SALES. If the cost and expenses exceed the recovery,
then the excess shall be credited against royalties payable by LICENSEE to
MOTOROLA hereunder in connection with sales or services in the country of such
legal proceedings, provided, however, that any such credit under this Paragraph
shall not exceed fifty percent (50%) of the royalties otherwise payable to
MOTOROLA with regard to sales or services in the country of such action in any
one calendar year, with any excess credit being carried forward to future
calendar years.

                        ARTICLE 7 - TERM AND TERMINATION

         7.1      This Agreement shall commence upon the EFFECTIVE DATE and
shall expire in each country on the date of expiration of the last to expire
patent included within PATENT RIGHTS in that country or if no patents issue
twenty (20) years from the EFFECTIVE DATE of this Agreement.

         7.2      LICENSEE and MOTOROLA shall exercise reasonable efforts to
develop and commercialize the LICENSED PRODUCTS using good scientific and
business judgment.

         7.3      Upon material breach or default of any of the terms and
conditions of this Agreement, the defaulting party shall be given written
notice of such default in writing and a period of sixty (60) days after receipt
of such notice to correct the default or breach or thirty (30) days in the case
of a financial default or breach. If the default or breach is not corrected
within the applicable sixty (60) or thirty (30) day period, the party not in
default shall have the right to terminate this Agreement.

         7.4      LICENSEE may terminate this Agreement and the license granted
herein, for any reason, upon giving MOTOROLA sixty (60) days written notice, or
such longer period as may be reasonably requested by MOTOROLA. Upon the giving
of notice of such termination, except as set forth in the next sentence, no
further amounts will be due or payable hereunder. If said termination is based
on a reasonable determination by LICENSEE's counsel that the manufacture, use,
sale or importation within the United States of America of LICENSED PRODUCTS
would, infringe upon rights of any third party, which were in the public domain
as of the EFFECTIVE DATE, LICENSEE shall be entitled to rescind the transaction
and be reimbursed by MOTOROLA for any monies paid to MOTOROLA, unless MOTOROLA
cures any potential infringement within such sixty (60) day

                                      14
<PAGE>   15

period.

         7.5      Termination under Paragraph 7.3 shall not affect MOTOROLA's
right to recover due and unpaid royalties or fees owed prior to the termination
date. Upon termination all rights in and to the licensed technology shall
revert to MOTOROLA at no cost to MOTOROLA, provided that MOTOROLA shall honor
sublicensee agreements in the event the sublicensee cures any payment defaults
which relate to that sublicense agreement and agrees to directly assume the
obligations of the LICENSEE under this Agreement and to make all payments
directly to MOTOROLA. In this connection MOTOROLA agrees to promptly issue,
from time to time, upon written request, estoppel certificates in favor of the
LICENSEE, AFFILIATED COMPANIES, sublicensees or potential sublicensees setting
forth the status of this Agreement and, if in default, the conditions required
to cure the same.

         7.6      In the event that the EFFECTIVE DATE has not occurred on or
before July 1, 2000, either party may terminate this Agreement by giving
written notice to the other party of such election. Upon any such termination,
neither party shall have any further obligations hereunder or under any of the
other agreements executed in connection with this Agreement.

                   ARTICLE 8 - REPRESENTATIONS AND WARRANTIES

         8.1      PATENT MATTERS: As of the Effective Date: (i) MOTOROLA
warrants and represents that it owns or has a license to the PATENT RIGHTS and
KNOW HOW, and that it has not made any commitments to others regarding the
PATENT RIGHTS and/or KNOW HOW in the LICENSED FIELD that would conflict with
such rights; (ii) MOTOROLA warrants and represents that it has not received
written notice from any third party that any composition, process or use
claimed by the PATENT RIGHTS infringes an issued patent of such third party;
(iii) MOTOROLA warrants and represents that it has no actual knowledge of any
current action conducted by a third party which is or would constitute an
infringement of the PATENT RIGHTS in the LICENSED FIELD; and (iv) MOTOROLA
warrants and represents that it has reviewed those portions of its intellectual
property portfolio which it believes are most relevant to the LICENSED FIELD
and believes that there are no other patents or patent applications owned by
MOTOROLA or licensed to MOTOROLA with the right to grant sublicenses which
would be infringed in the practice of the

                                      15
<PAGE>   16

PATENT RIGHTS in the LICENSED FIELD in the TERRITORY. Should it later eventuate
that any patent or patent application, that is owned by MOTOROLA or licensed to
MOTOROLA with the right to grant sublicenses, would be infringed in the
practice of the PATENT RIGHTS in the LICENSED FIELD in the TERRITORY, then that
patent or patent application shall be deemed to be licensed to LICENSEE as part
of the PATENT RIGHTS under this Agreement; and (v) MOTOROLA represents and
warranties that the rights and options granted to LICENSEE under this Agreement
are free and clear of liens, claims and encumbrances of any third parties.

         8.2      OTHER REPRESENTATIONS: Each party warrants and represents to
the other party that it has the legal power to enter into this Agreement, that
this Agreement constitutes a binding agreement enforceable against such party
in accordance with its terms, and that is has not made any commitments to
others that would conflict with its obligations under this Agreement.

            ARTICLE 9 - CROSS-LICENSE OF FUTURE DEVELOPED TECHNOLOGY

         9.1      MOTOROLA and LICENSEE are parties to the DEVELOPMENT
AGREEMENT under which any patent rights arising out of or in connection with
that agreement will be owned and controlled by LICENSEE. "LICENSEE FUTURE
PATENT RIGHTS" are those patents and patent applications that are owned by
LICENSEE as described above. LICENSEE agrees to license the LICENSEE FUTURE
PATENT RIGHTS to MOTOROLA worldwide, with the right to grant sublicenses, in
all fields other than the LICENSED FIELD. The license granted to MOTOROLA as
described above shall be royalty free except for sublicenses, in which event
MOTOROLA shall owe LICENSEE a fee equal to that which LICENSEE would owe
MOTOROLA under this AGREEMENT had the sublicense been from LICENSEE for a
LICENSED PRODUCT. LICENSEE shall be responsible for handling patent prosecution
of all patent applications based on LICENSEE FUTURE PATENT RIGHTS.

         9.2      "MOTOROLA FUTURE PATENT RIGHTS" are those patents and patent
applications (other than the PATENT RIGHTS) relating to the specific fields of
wireless EKG technology and other wireless medical sensor technologies (such as
vital signs and pulse oximetry, but excluding glucose monitoring) that are now
or hereafter owned or controlled by MOTOROLA during the term of the DEVELOPMENT
AGREEMENT which would be useful to LICENSEE in

                                      16
<PAGE>   17

providing new and innovative products (the "MEDICAL FIELD"). MOTOROLA agrees to
grant LICENSEE the option to license the MOTOROLA FUTURE PATENT RIGHTS to
LICENSEE in the MEDICAL FIELD under the royalty provisions of this AGREEMENT
and MOTOROLA shall supplement the PATENT RIGHTS transferred hereunder by
periodically providing a supplemental schedule of PATENT RIGHTS to LICENSEE.
MOTOROLA shall be responsible for handling all patent prosecution of the
MOTOROLA FUTURE PATENT RIGHTS and enforcement of the MOTORALA FUTURE PATENT
RIGHTS shall be in accordance with the enforcement provisions for the PATENT
RIGHTS as described above.

         9.3      In the event MOTOROLA elects not to prosecute or maintain its
FUTURE PATENT RIGHTS as described above, it shall give the LICENSEE notice of
such fact in a timely manner so as to allow the continuation of such patent
prosecutions or maintenance, in which event LICENSEE shall have no future
obligations to pay royalties or other fees associated with such patent rights
in the applicable jurisdictions.

                           ARTICLE 10 - MISCELLANEOUS

         10.1     All notices pertaining to this Agreement shall be in writing
and sent certified mail, return receipt requested, or by other commercial
delivery means to the parties at the following addresses or such other address
as such party shall have furnished in writing to the other party in accordance
with this Paragraph:

FOR MOTOROLA:              Assistant General Counsel and Director, Patents,
                           Trademarks and Licensing
                           Motorola, Inc.
                           1301 East Algonquin Road
                           Schaumburg, IL 60196

FOR LICENSEE:              Bart Chernow, M.D.
                           President
                           GMP|Wireless Medicine, Inc.
                           One East Broward Blvd.
                           Ft. Lauderdale, FL  33301

                                      17
<PAGE>   18

         10.2     All written progress reports, royalty and other payments, and
any other related correspondence shall be in writing and sent to:

FOR MOTOROLA:              Assistant General Counsel and Director, Patents
                           Trademarks and Licensing
                           Motorola, Inc.
                           1301 East Algonquin Road
                           Schaumburg, IL 60196

         10.3     This Agreement is binding upon and shall inure to the benefit
of MOTOROLA, its successors and assignees and shall not be assignable to
another party without the written consent of MOTOROLA, which consent shall not
be unreasonably withheld, except that the LICENSEE shall have the right to
assign this Agreement to another party without the consent of MOTOROLA in the
case of the sale or transfer by the LICENSEE of all, or substantially all, of
its assets relating to the LICENSED PRODUCT to that party.

         10.4     In the event that any one or more of the provisions of this
Agreement should for any reason be held by any court or authority having
jurisdiction over this Agreement, or over any of the parties hereto to be
invalid, illegal or unenforceable, such provision or provisions shall be
reformed to approximate as nearly as possible the intent of the parties, and if
unreformable, shall be divisible and deleted in such jurisdictions; elsewhere,
this Agreement shall not be affected.

         10.5     The construction, performance, and execution of this
Agreement shall be governed by the laws of the State of Delaware without regard
to that State's conflict of law provisions.

         10.6     Prior to initial human testing or first commercial sale of
any LICENSED PRODUCT as the case may be in any particular country, the LICENSEE
shall establish and maintain, in each country in which LICENSEE, an AFFILIATED
COMPANY or sublicensee shall test or sell LICENSED PRODUCT(S) and LICENSED
SERVICES, product liability or other appropriate insurance coverage appropriate
to the risks involved in marketing LICENSED PRODUCT(S). Upon MOTOROLA'S
request, the LICENSEE will furnish MOTOROLA with a Certificate of Insurance of
each product liability insurance policy obtained.

         10.7     This Agreement and the documents referred to herein and in
the documents attached hereto constitute the entire understanding between the
parties with respect to the obligations of the parties with respect to the
subject matter hereof, and supersedes and replaces all prior agreements,

                                      18
<PAGE>   19

understandings, writings, and discussions between the parties relating to said
subject matter, including without limitation the LICENSE AGREEMENT.

         10.8     This Agreement may be amended and any of its terms or
conditions may be waived only by a written instrument executed by the
authorized officials of the parties or, in the case of a waiver, by the party
waiving compliance. The failure of either party at any time or times to require
performance of any provision hereof shall in no manner affect its right at a
later time to enforce the same. No waiver by either party of any condition or
term in any one or more instances shall be construed as a further or continuing
waiver of such condition or term or of any other condition or term.

         10.9     This Agreement shall be binding upon and inure to the benefit
of and be enforceable by the parties hereto and their respective successors and
permitted assigns.

         10.10    Upon termination of this Agreement for any reason, Paragraphs
5.3 and 7.5 shall survive termination of this Agreement.

         10.11    This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same instrument.

         10.12    The dispute resolution process set forth in Section 10.1 of
the DEVELOPMENT AGREEMENT between the parties shall apply to this Agreement.

                                      19
<PAGE>   20

         IN WITNESS WHEREOF the respective parties hereto have executed this
Agreement by their duly authorized officers on the date appearing below their
signatures.

MOTOROLA, INC.                                   GMP|WIRELESS MEDICINE, INC.

By:                                              By:
   -------------------------------------------      ---------------------------
   Jonathan Meyer                                   Bart Chernow, M.D.
   Senior Vice President, Assistant General         President
   Counsel and Director of Patents, Trademarks      GMP|Wireless Medicine, Inc.
   and Licensing Motorola, Inc.                     One East Broward Boulevard
   1303 East Algonquin Road                         Suite 1701
   Schaumburg, IL 60196                             Fort Lauderdale, FL  33301

By:
   ------------------------------------------
   Keith J. Bane
   Executive Vice President and President
   Global Strategy and Business Development
   Motorola, Inc.
   1303 East Algonquin Road
   Schaumburg, IL  60196

                                      20
<PAGE>   21

Appendix A - Patent Rights

Exhibit A - Development Agreement
Exhibit B - Stock Acquisition Agreement
Exhibit C - Shareholders' Agreement

                                      21
<PAGE>   22

                                   Appendix A

<TABLE>
<S>      <C>
1.       U.S. Patent No. 5,862,803     Issued January 26, 1999         USSN  08/605,197
         "Wireless Medical Diagnosis and Monitoring Equipment"
         Besson, Von Czettriz and Bax, inventors

2.       U.S. Patent No. 5,957,854     Issued September 28, 1999       USSN  08/985,673
         "Wireless Medical Diagnosis and Monitoring Equipment"
         Besson, Von Czettriz and Bax, inventors

3.       U.S. Patent Application Serial No. 09/379,763        Filed September 28, 1999
         "Wireless Medical Diagnosis and Monitoring Equipment"
         Besson, Von Czettriz and Bax, inventors

4.       European Patent No. EP0719108C                       Filed September 2, 1994
         "Wireless Medical Diagnosis and Monitoring Equipment"
         Besson, Von Czettriz and Bax, inventors

5.       U.K. Patent corresponding to EP0719108C
         "Wireless Medical Diagnosis and Monitoring Equipment"
         Besson, Von Czettriz and Bax, applicants and inventors

6.       French Patent corresponding to EP0719108C
         "Wireless Medical Diagnosis and Monitoring Equipment"
         Besson, Von Czettriz and Bax, inventors

7.       German Patent corresponding to EP0719108C
         "Wireless Medical Diagnosis and Monitoring Equipment"
         Besson, Von Czettriz and Bax, inventors

8.       German Patent Application Serial No. 4329898.2
         "Wireless Medical Diagnosis and Monitoring Equipment"

9.       U.S. Patent Application for "Optical Non Invasive Blood Pressure Sensor and Method" (McDonnell Docket
         No. MBHB 00-212)

10.      U.S. Patent Application for "Method for Obtaining Blood Pressure Data From Optical Sensor" (McDonnell
         Docket No. MBHB 00-213)

11.       U.S. Patent Application for "Programmable Wireless Electrode System For Medical Monitoring" (Serial No.
         09/551,718; McDonnell Docket No. MBHB 00-214)

12.      U.S. Patent Application for "Wireless System Protocol for Telemetry Monitoring" (Serial No. 09/551,719;
         McDonnell Docket No. MBHB 00-214-A)
</TABLE>

                                      22
<PAGE>   23

<TABLE>
<S>      <C>
13.      U.S. Patent Application for "Wireless EKG" filed July 18, 2000
</TABLE>

                                      23<PAGE>   1
                                                                  EXHIBIT 10.14

                          EXCLUSIVE LICENSE AGREEMENT

                                    BETWEEN

                     CHILDREN'S MEDICAL CENTER CORPORATION

                                      AND

                    GMP|DIAGNOSTIC|PROGNOSTIC MARKERS, INC.

                            FOR THE MOSES LABORATORY

<PAGE>   2

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
Articles                                                                          Page

<S>             <C>                                                               <C>
I.              Definitions                                                         1

II.             Grant                                                               5

III.            Due Diligence                                                       6

IV.             Royalties and Other Payments                                        8

V.              Reports and Records                                                10

VI.             Patent Prosecution                                                 11

VII.            Infringement                                                       12

VIII.           Uniform Indemnification and Insurance Provisions                   13

IX.             Export Controls                                                    14

X.              Non-Use of Names                                                   15

XI.             Assignment                                                         15

XII.            Dispute Resolution and Arbitration                                 15

XIII.           Term and Termination                                               16

XIV.            Payments, Notices and Other Communications                         17

XV.             General Provisions                                                 18
</TABLE>

<PAGE>   3

                          EXCLUSIVE LICENSE AGREEMENT

         This Agreement is made and entered into as of the date last written
below (the Effective Date), by and between CHILDREN'S MEDICAL CENTER
CORPORATION, a charitable corporation duly organized and existing under the
laws of the Commonwealth of Massachusetts and having its principal office at
300 Longwood Avenue, Boston, Massachusetts, 02115, U.S.A. (hereinafter referred
to as "CMCC"), and GMP|Diagnostic|Prognostic Markers, Inc., a business
corporation organized and existing under the laws of the State of Delaware and
having its principal office at One East Broward Boulevard, Suite 1701, Fort
Lauderdale, FL, 33301 (hereinafter referred to as "Licensee").

         WHEREAS, CMCC is the owner of certain Patent Rights (as that term
shall be defined hereafter) and has the right to grant exclusive licenses under
said Patent Rights, subject only to a royalty-free, nonexclusive license
heretofore granted to the United States Government for those patents developed
with U.S. Government funding;

         WHEREAS, CMCC desires to have the Patent Rights utilized in the public
interest and is willing to grant a license thereunder on the terms and
conditions described herein;

         WHEREAS, Licensee has represented to CMCC that Licensee is ready,
willing and able to engage in the commercial development, production,
manufacture, marketing and sale of Marker Panel Products (as that term shall be
defined hereafter) and/or the use of Marker Panel Processes (as that term shall
be defined hereafter) and that it shall commit itself to a thorough, vigorous
and diligent program of exploiting the Patent Rights in accordance with the
terms and conditions described herein so that public utilization shall result
therefrom; and

         WHEREAS, the Burnham Institute and CMCC have agreed to (i) work
together and pool the efforts of their respective inventors in the research and
development of Marker Panel Products and Marker Panel Processes and (ii) share
in the proceeds resulting from these joint efforts regardless of which
institution's patent rights are required for commercialization of the Marker
Panel Products and Marker Panel Processes;

         WHEREAS, Licensee desires to obtain an exclusive license under the
Patent Rights on the terms and conditions of this Agreement.

         NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained herein, the parties hereto agree as follows:

                             ARTICLE I. DEFINITIONS

         For the purpose of this Agreement, the following words and phrases
shall have the meanings set forth below:

         A.       "Affiliate" shall mean any company or other legal entity
controlling, controlled by or under common control with Licensee. For purposes
of the definition of "Affiliate" the term "control" shall mean: (i) in the case
of a corporate entity, the direct or indirect ownership of at least a majority
of the stock or participating shares entitled to vote for the election of
directors of that entity; (ii) in the case of a partnership, the power
customarily held by a general partner to direct the management and policies of
such partnership; or (iii) in the case of a joint venture,

                                       1
<PAGE>   4

whether in corporate, partnership or other legal form, a more than nominal
economic interest and managerial role.

         B.       "Burnham License" shall mean the License Agreement between
the Burnham Institute and Licensee of even date pertaining to the patent rights
identified in Appendix 1.

         C.       "Combination Product(s) or Process(es)" shall mean a product
or process that includes a Marker Panel Product or Marker Panel Process (the
"Licensed Components") sold in combination with another component(s) whose
manufacture, use or sale by an unlicensed party would not constitute an
infringement of the Patent Rights under this Agreement or the Burnham License
(the "Unlicensed Components").

         D.       "Field of Use" shall mean the diagnosis or prognosis of any
disease or condition in humans or animals.

         E.       "First Commercial Sale" shall mean: (i) the first sale of any
Marker Panel Product or Marker Panel Process by Licensee or a Sublicensee,
following approval of such Marker Panel Product's or Marker Panel Process's
marketing by the appropriate governmental agency, if any such approval is
necessary, for the country in which the sale is to be made; or (ii) when
governmental approval is not required, the first sale of that Marker Panel
Product or Marker Panel Process.

         F.       "Know-how" shall mean any and all manufacturing information,
technical information, testing and analytic methods and specifications which
CMCC owns or has sufficient rights to include in the license grant in Article
II hereof, necessary for research, development or manufacture of any Marker
Panel Product or Marker Panel Process in the Field(s) of Use, deriving from the
activities of the Principal Investigator and/or any other Research Program
personnel in the performance of the Sponsored Research Agreement.

         G.       "Licensed Product" shall mean any product or part thereof:

                  1.       The manufacture, use or sale of which would infringe
                           any one of the issued, valid, enforceable, unexpired
                           claim(s) or any one of the pending claim(s)
                           contained in the Patent Rights in any country.

                  2.       The manufacture of which uses a "Licensed Process"
                           as that term shall be defined hereafter.

         H.       "Licensed Process " shall mean any process that would
infringe any one of the issued, valid, enforceable, unexpired claim(s) or any
one of the pending claim(s) contained in the Patent Rights in any country.

         I.       "Licensee" shall mean Licensee and/or its successor(s) or
assignee(s) and/or its Affiliates.

         J.       "Marker Panel Product" shall mean any product or part
thereof:

                  1.       The manufacture, use or sale of which in any country
                           would infringe any one of the issued, valid,
                           enforceable, unexpired claim(s) or any one of the
                           pending claim(s) contained in any of the patent
                           rights under the Burnham

                                       2
<PAGE>   5

                           License or the License Agreement of even date
                           pertaining to patent rights identified in Appendix 3
                           from the Moses laboratory or Patent Rights under
                           this Agreement.

                  2.       The manufacture of which uses a "Marker Panel
                           Process " as that term shall be defined hereafter.

         K.       "Marker Panel Process" shall mean any process that would
infringe any one of the issued, valid, enforceable, unexpired claim(s) or any
one of the pending claim(s) contained in the patent rights under the Burnham
License or or the License Agreement of even date pertaining to patent rights
identified in Appendix 3 from the Zetter laboratory or Patent Rights under this
Agreement.

         L.       "Net Sales" shall mean gross receipts received by Licensee,
or Licensee's Affiliates for Marker Panel Products and Marker Panel Processes
produced hereunder, less the sum of the following:

                  1.       Trade, quantity or cash discounts (including
                           refunds, rebates, chargebacks and retroactive price
                           adjustments) allowed in amounts customary in the
                           trade.

                  2.       Sales taxes, tariff duties and/or use taxes directly
                           imposed and with reference to particular sales.

                  3.       Freight, storage and delivery charges (including
                           insurance premiums related to transportation and
                           delivery) prepaid or allowed to the extent reflected
                           on the customer's invoice.

                  4.       Amounts allowed or credited on returns.

No deductions shall be made for commissions paid to individuals whether they
are with independent sales agencies or regularly employed by Licensee and on
its payroll or for the cost of collections. Marker Panel Products and Marker
Panel Processes shall be considered "sold" when billed out or invoiced. For
purposes of this Agreement, the sale or use of a Marker Panel Product or Marker
Panel Process by a Sublicensee shall not be included in the calculation of Net
Sales. Notwithstanding anything herein to the contrary, the following shall not
be considered a sale of a Marker Panel Product or Marker Panel Process under
this Agreement: (i) the transfer of a Marker Panel Product or Marker Panel
Process to an Affiliate for sale by the Affiliate in a transaction that will be
royalty bearing; (ii) the transfer of a Marker Panel Product or Marker Panel
Process to a third party without consideration to Licensee in connection with
the development or testing of that Marker Panel Product or Marker Panel
Process; or (iii) the transfer of a Marker Panel Product or Marker Panel
Process to a third party without consideration in connection with the marketing
or promotion of the Marker Panel Product or Marker Panel Process.

         M.       "Patent Rights" shall mean all of the following intellectual
property that CMCC owns or has rights to during the term of this Agreement:

                                       3
<PAGE>   6

                  1.       The United States and foreign patents and/or patent
                           applications listed in Appendix 3 attached hereto
                           and incorporated herein by reference and divisionals
                           and continuations thereof.

                  2.       The United States and foreign patents issued from
                           the applications listed in Appendix 3 and from
                           divisionals and continuations of those applications.

                  3.       Claims of United States and foreign
                           continuation-in-part, improvement or enhancement
                           applications, and of the resulting patents, which
                           relate to the subject matter specifically described
                           in the United States and foreign patent applications
                           described in Appendix 3.

                  4.       Claims of all later filed foreign patent
                           applications, and of the resulting patents, which
                           relate to subject matter specifically described in
                           the United States patent and/or patent applications
                           described in subparagraphs 1, 2 or 3 of this Article
                           I, Paragraph M.

5.                         Any reissues, divisions, amendments or extensions of
                           the United States or foreign patents described in
                           subparagraphs 1, 2, 3 or 4 of this Article I,
                           Paragraph M.

                  6.       Claims of all United States and foreign patent
                           applications and patents resulting from the
                           Sponsored Research Agreement and licensed by
                           Licensee in accordance with the terms of the Moses
                           Sponsored Research Agreement.

         N.       "Research Program" shall mean the research program between
Licensee and Children's Hospital Boston which is sponsored by Licensee pursuant
to the Moses Sponsored Research Agreement.

         O.       "Sublicensee" shall mean a person or entity unaffiliated with
Licensee to whom Licensee has granted an arm's length sublicense under this
Agreement.

         P.       "Sublicense Consideration" shall mean consideration of any
kind received by the Licensee from a sublicense for sales of Marker Panel
Products or Marker Panel Processes or fees received, in whatever form
(including, without limitation, cash, securities or in kind consideration),
such as upfront fees or milestone fees and including any premium paid by the
Sublicensee over Fair Market Value for stock of the Licensee received in
consideration for such sublicense. However, not included in Sublicense
Consideration are amounts paid to the Licensee by the Sublicensee for Marker
Panel Product development, research work, clinical studies and regulatory
approvals performed by or for the Licensee, or third parties on their behalf
pursuant to a specific agreement including a performance plan and commensurate
budget related to the Marker Panel Product. The term "Fair Market Value for
stock" as used in this Paragraph shall mean the average of the closing prices
of the stock on all securities exchanges on which the stock may at the time be
listed or, if there have been no sales on any such exchange on the date the
value is being determined (the "Valuation Date"), the average of the highest
bid and lowest asked prices on all such exchanges at the end of the Valuation
Date, or, if the stock is not so listed, the average of the representative bid
and asked prices quoted in the NASDAQ System as of 4:00 p.m., New York time, on
the Valuation Date or, if on such day

                                       4
<PAGE>   7

the stock is not quoted in the NASDAQ System, the average of the highest bid
and lowest asked prices on the Valuation Date in the domestic over-the-counter
market as reported by the National Quotation Bureau Incorporated, or any
similar successor organization, in each such case averaged over a period of
twenty (20) days consisting of the Valuation Date and the nineteen (19)
consecutive business days prior to such day. If on the Valuation Date the stock
is not listed on any securities exchange or quoted in the NASDAQ System or the
over-the-counter market, the Fair Market Value of each share of such stock
shall be the fair market value of a share of the stock as of the Valuation
Date, as reasonably determined by the Board.

         Q.       "Moses Sponsored Research Agreement" shall mean that certain
Sponsored Research Agreement between the parties, of even date including any
extensions and renewals of the same pertaining to Research Program in the
laboratory of Dr. Marsha Moses.

                               ARTICLE II. GRANT

         A.       CMCC hereby grants to Licensee the worldwide right and
exclusive license to make, have made, use, lease and sell the Licensed Products
and to practice the Licensed Processes for the Field of Use to the end of the
term for which the Patent Rights are granted, unless sooner terminated as
provided in this Agreement.

         B.       Notwithstanding anything above to the contrary, CMCC shall
retain a royalty-free, nonexclusive, irrevocable license to practice, and to
sublicense other non-profit research organizations to practice, the Patent
Rights for noncommercial research purposes only. For purposes of this
paragraph, noncommercial research purposes shall exclude the practice of the
Patent Rights to perform clinical research for a for-profit organization, to
produce or manufacture Marker Panel Products for general sale, or to perform
diagnostic or prognostic services for a fee.

         C.       The license granted hereunder shall be subject to the rights
of the United States government, if any, under Public Laws 96-517, 97-226, and
98-620, codified at 35 U.S.C. sec. 200-212 and any regulations promulgated
thereunder.

         D.       CMCC hereby grants to Licensee the worldwide, irrevocable,
perpetual right and non-exclusive license to practice Know-How to develop,
test, make, have made, use, sell, have sold, offer for sale and import for use
or resale the Marker Panel Products and Marker Panel Processes.

         E.       Licensee agrees that Marker Panel Products leased or sold in
the United States shall be manufactured substantially in the United States.

         F.       In order to establish exclusivity for Licensee, CMCC hereby
agrees that it shall not, without Licensee's prior written consent, grant to
any other commercial party a license to make, have made, use, lease and/or sell
Licensed Products or to use the Licensed Processes in the Field of Use during
the period of time in which this Agreement is in effect, except as otherwise
specified in this Agreement or as required by law to grant rights to the United
States Government.

         G.       Licensee shall have the right to enter into sublicensing
agreements with respect to any of the rights, privileges, and licenses granted
hereunder, subject to the terms and

                                       5
<PAGE>   8

conditions hereof. Such sublicenses will terminate upon the termination of
Licensee's rights granted herein unless events of default are cured by Licensee
or Sublicensee within thirty (30) days of notification by CMCC of default
and/or as provided by the terms of this Agreement.

         H.       Licensee agrees that any sublicense granted by it shall
provide that the obligations to CMCC of Articles II (Grant), V (Reports and
Records), VII (Infringement), VIII (Insurance and Indemnification), IX (Export
Controls), X (Non-Use of Names), XI (Assignment), XII (Dispute Resolution),
XIII (Term and Termination) and XV (Miscellaneous Provisions) of this Agreement
shall be binding upon the Sublicensee as if it were a party to this Agreement.
Licensee further agrees to attach a copy of this Agreement to all sublicense
agreements, deleting economic terms when and as appropriate.

         I.       Licensee agrees to provide to CMCC notice of any sublicense
granted hereunder and to forward to CMCC a copy of any and all fully executed
sublicense agreements. Licensee further agrees to forward to CMCC annually a
copy of such reports received by Licensee from its Sublicensees during the
preceding twelve (12) month period as shall be pertinent to a royalty
accounting under the applicable sublicense.

         J.       Licensee shall notify CMCC in writing of any Sublicensee
Consideration.

         K.       CMCC agrees that if Licensee has provided to CMCC notice that
Licensee has granted a sublicense to a Sublicensee under this Agreement, then
in the event CMCC terminates this Agreement for any reason provided hereafter,
CMCC shall provide to such Sublicensee no less than thirty (30) days prior to
the effective date of said termination, written notice of said termination at
the address specified by Licensee to CMCC in Licensee's notice to CMCC under
Paragraph I of this Article II. CMCC agrees that upon the Sublicensee's notice
as described below and provided the Sublicensee is not in breach of its
sublicense, CMCC shall grant to such Sublicensee license rights and terms
equivalent to the sublicense rights and terms which the Licensee shall have
granted to said Sublicensee; provided that the Sublicensee shall remain a
Sublicensee under this Agreement for a period of at least sixty (60) days
following receipt of notice from CMCC. Sublicensee shall during said sixty (60)
day period provide to CMCC notice wherein the Sublicensee: (i) reaffirms the
terms and conditions of this Agreement as it relates to the rights the
Sublicensee has been granted under the sublicense; (ii) agrees to abide by all
of the terms and conditions of this Agreement applicable to Sublicensees and to
discharge directly all pertinent obligations of Licensee which Licensee is
obligated hereunder to discharge; and (iii) acknowledges that CMCC shall have
no obligations to the Sublicensee other than its obligations set forth in this
Agreement with regard to Licensee.

         L.       The license granted hereunder shall not be construed to
confer any rights upon Licensee by implication, estoppel or otherwise as to any
technology not described in the Patent Rights.

                           ARTICLE III. DUE DILIGENCE

         A.       In the event Licensee decides not to exploit a licensed
Patent Right or expend the resources required to meet the Development Plan
milestones, it shall promptly inform CMCC in writing and shall surrender to
CMCC its license to that Patent Right for the specific field(s) of use or
territory not being exploited. Licensee shall use Commercially Reasonable
Efforts to develop and commercialize one or more Marker Panel Products directly
or through its

                                       6
<PAGE>   9

Sublicensees; and shall continue to use Commercially Reasonable Efforts to
develop and commercialize one or more Marker Panel Products throughout the term
of this Agreement. "Commercially Reasonable Efforts" for purposes of this
Article III shall mean efforts and resources commonly used in the
research-based prognostic or diagnostic industries for a product at a similar
stage in its product life of similar market potential taking into account
efficacy, the competitiveness of alternative products in the marketplace, the
patent and other proprietary position of the product, the likelihood of
regulatory approval given the regulatory structure involved, the profitability
of the product and alternative products and other relevant factors.

         B.       The parties acknowledge that Licensee has provided to CMCC
prior to the date of execution of this Agreement a written commercialization
development plan ("Development Plan") setting forth the initial indications and
markets for Marker Panel Products and Marker Panel Processes, including to the
extent practicable: (i) time-delimited targets for pre-clinical development,
clinical trials, regulatory approval, manufacturing and marketing that
represent Commercially Reasonable Efforts to bring Marker Panel Products and
Marker Panel Processes to the marketplace; and (ii) actual or projected
financial resources and/or strategic alliances that will be required to
implement the Development Plan. The Development Plan is attached hereto as
Appendix 4.

         C.       Licensee shall use Commercially Reasonable Efforts to
accomplish the milestones set forth in the Development Plan and to manufacture
and distribute Marker Panel Products and Marker Panel Processes. Licensee shall
be deemed to have used such Commercially Reasonable Efforts for the first three
years of this Agreement so long as it has or has caused third parties to timely
fund the Moses Sponsored Research Agreement.

         D.       Notwithstanding anything above to the contrary, CMCC shall
not unreasonably withhold its assent to any revision of the objective(s) set
forth in the Development Plan when requested in writing by Licensee and
supported by evidence reasonably acceptable to CMCC: (i) of technical
difficulties or delays in the clinical studies or regulatory process that
Licensee could not have reasonably avoided; or (ii) that Licensee, its
Affiliates and/or Sublicensees have expended good faith and diligent efforts
and adequate resources to meet said objective.

         E.       In the event CMCC reasonably believes that Licensee is not
diligently seeking to achieve the objectives set forth in the Development Plan
in a timely manner, CMCC shall so notify Licensee in writing. Licensee shall
have the option, exercisable by written notice to CMCC provided within ten (10)
days after receipt of any such notice, to either: (i) receive a three (3)
months grace period to establish to CMCC's reasonable satisfaction that
Licensee is expending sufficient resources to achieve said objectives; or (ii)
agree to CMCC's termination of this Agreement as provided hereafter. In the
event Licensee agrees to termination of this Agreement, CMCC shall immediately
terminate the license granted to Licensee under this Agreement. In the event
Licensee fails to establish its diligence to CMCC's reasonable satisfaction as
provided above prior to expiration of the three (3) months grace period, CMCC
shall have the right to terminate the license granted to Licensee under this
Agreement or to convert the license to a non-exclusive license as to any Patent
Rights for which the development obligation has not been met on financial terms
and conditions mutually agreed to by CMCC and Licensee. Pursuant to Article
XII, Licensee is entitled to arbitration regarding the factual issue of whether
any determination by CMCC that Licensee failed to diligently seek to achieve
the objectives set forth in the Development Plan was reasonable.

                                       7
<PAGE>   10
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         F.       In the event Licensee fails to meet the objective(s) set
forth in the Development Plan in a timely manner, CMCC shall notify Licensee
thereof in writing, and Licensee shall have thirty (30) days following such
notification to establish to the reasonable satisfaction of CMCC that (i) it
has met such objective(s); or (ii) a revision to the Development Plan is
necessary and appropriate as contemplated above. In the event Licensee fails to
establish the same to CMCC's reasonable satisfaction, CMCC shall have the right
in its discretion to terminate the license granted to Licensee under this
Agreement or to convert the license granted to Licensee hereunder to a
non-exclusive license as to any Patent Rights for which the development
obligation has not been met on financial terms and conditions mutually agreed
to by CMCC and Licensee.

                    ARTICLE IV. ROYALTIES AND OTHER PAYMENTS

         A.       For the rights, privileges and exclusive licenses granted
hereunder, Licensee shall pay to CMCC the following amounts in the manner
hereinafter provided until the end of the term of the last to expire Patent
Right, unless this Agreement shall be sooner terminated as hereinafter
provided:

                  1.       A license issue fee of [***], which license issue fee
                  shall be deemed earned and due immediately upon the execution
                  of this Agreement.

                  2.       Licensee shall reimburse CMCC for expended patent
                  costs to date in the amount of [***] due immediately upon
                  receipt of an invoice and supporting documentation.

                  3.       Licensee shall make the following one-time milestone
                  payment to CMCC upon the occurrence of the following event
                  ("Milestone"):

                           [***] upon the First Commercial Sale of the first
                           Marker Panel Product or Marker Panel Process in any
                           country.

                  4.       A License Maintenance Fee of [***] which shall be
                  payable on January 1, 2001, and on January 1 of each
                  subsequent year thereafter during the exclusive license period
                  of this Agreement. Notwithstanding anything herein to the
                  contrary, any Running Royalties (defined below) subsequently
                  due to CMCC on Net Sales of Marker Panel Products and Marker
                  Panel Processes, if any, for each such year shall be
                  creditable against the License Maintenance Fee for said year.
                  License Maintenance Fees paid in excess of Running Royalties
                  shall not be creditable against Running Royalties due in
                  future years. In addition, no License Maintenance Fee shall be
                  due in any year in which Licensee is funding the Research
                  Program.

                  5.       Running Royalties in an amount equal to [***] of the
                  first [***] cumulative of Net Sales of Marker Panel Products
                  or Marker Panel Processes used, leased or sold by and/or for
                  Licensee and/or its Affiliates and [***] of Net Sales over
                  that amount.

                                       8
<PAGE>   11
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                  6.       In the event Licensee has granted sublicenses under
                  this Agreement, [***] of Sublicense Consideration.

         B.       No multiple royalties shall be payable because any Marker
Panel Product or Marker Panel Process, its manufacture, use, lease or sale are
or shall be covered by more than one Patent Rights patent application or Patent
Rights patent licensed under this Agreement.

         C.       To the extent that Licensee obtains subsequent to the date of
this Agreement licenses to third party (other than the Burnham Institute)
patents or other intellectual property that are necessary to produce or sell
the specific markers covered by the patent rights under the Burnham License,
the patent rights identified in Appendix 2 from the Moses laboratory, or the
Patent Rights under this Agreement for Marker Panel Products or Marker Panel
Processes, Licensee may deduct from the royalty due to CMCC fifteen percent
(15%) of the royalties due on such third party patents or intellectual property
up to an amount equal to fifty percent (50%) of royalties hereunder.

         D.       For purposes of calculating royalties for a Combination
Product or Process one of the following methods will be used:

                  1.       By multiplying the Net Sales of the Combination
                  Product or Combination Process during the applicable royalty
                  accounting period ("accounting period") by a fraction, the
                  numerator of which is the aggregate gross selling price of the
                  Licensed Component(s) contained in the Combination Product or
                  Combination Process if sold separately, and the denominator of
                  which is the sum of the gross selling price of the Licensed
                  Component(s), and the Unlicensed Component(s) contained in the
                  Combination Product or Combination Process if sold separately;
                  or

                  2.       In the event that no such separate sales are made of
                  the Licensed Component(s) or the Unlicensed Components during
                  the applicable accounting period, Net Sales for purposes of
                  determining royalties payable hereunder shall be calculated by
                  multiplying the Net Sales of the Combination Product or
                  Combination Process by a fraction, the numerator of which is
                  the fair market value of the Licensed Component(s) and the
                  denominator of which is the sum of the fair market value of
                  the Licensed Component(s) and the Unlicensed Component(s)
                  contained in the Combination Product or Combination Process.

         E.       Royalty payments shall be paid in United States dollars in
Boston, Massachusetts, or at such other place as CMCC may reasonably designate
consistent with the laws and regulations controlling in any foreign country. If
the currency conversion shall be required in connection with the payments of
royalties or other amounts hereunder, the conversion shall be made by using the
exchange rate prevailing at the Fleet Bank on the last business day of the
calendar quarterly reporting period to which such royalty payments relate.

         F.       The royalty payments set forth in this Agreement shall, if
overdue, bear interest until payment at a per annum rate of four percent (4%)
above the prime rate in effect at the Fleet Bank on the due date. The payment
of such interest shall not foreclose CMCC from

                                       9
<PAGE>   12
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

exercising any other rights it may have under this Agreement as a consequence
of the lateness of any payment.

         G.       In consideration of the issuance of the license of the Patent
Rights as contained in this Agreement, Licensee shall issue a total of [***]
shares of Common Stock of Licensee, $.001 par value per share, (the "Shares") in
the name of CMCC. Licensee represents to CCMC that, as of the Effective Date,
the aggregate number of Shares equals no less than [***] of the Licensee's
issued and outstanding Common Stock calculated on a "Fully Diluted Basis." For
purposes of this Paragraph, "Fully Diluted Basis" shall mean that the total
number of issued and outstanding shares of the Licensee's Common Stock shall be
calculated to include conversion of all issued and outstanding securities then
convertible into common stock, the exercise of all then outstanding options and
warrants to purchase shares of common stock, whether or not then exercisable,
and shall assume the issuance or grant of all securities reserved for issuance
pursuant to any Licensee stock or stock option plan in effect on the date of the
calculation.

         H.       The equity interest held by CMCC would not be diluted below
[***] on a fully diluted basis until the earlier of (i) an initial public
offering of securities by Licensee, or (ii) the funding of Licensee by GMP
Companies or other entity has reached [***].

                         ARTICLE V. REPORTS AND RECORDS

         A.       Licensee shall keep, and shall require its Affiliates and
Sublicensees to keep, full, true and accurate books of account in accordance
with generally accepted accounting principles and containing sufficient detail
to enable CMCC to determine the royalty and other amounts payable to CMCC under
this Agreement. Said books of account shall be kept at Licensee's principal
place of business or the principal place of business of the appropriate
division of Licensee to which this Agreement relates. Said books and the
supporting data shall be retained for at least five (5) years following the end
of the calendar year to which they pertain.

         B.       CMCC shall have the right to audit the books of account
described above from time to time to the extent necessary to verify the reports
provided for herein or compliance in other respects with this Agreement. CMCC
or its agents shall perform these audits at CMCC's expense during Licensee's
regular business hours.

         C.       Licensee shall deliver to CMCC true and accurate reports by
March 31, for the period July 1 through December 31 of the previous year, and
on September 30, for the period January 1 through June 30 of the current year,
giving such particulars of the business conducted by Licensee, its Affiliates
and its Sublicensees under this Agreement as shall be pertinent to a royalty
accounting hereunder and to verify Licensee's activities with respect to
achieving the objectives of the Development Plan described in Article III
above. These reports shall include at least the following:

                  1.       Number of Marker Panel Products and Marker Panel
                           Processes manufactured and sold.

                                      10
<PAGE>   13

                  2.       Aggregate billings for Marker Panel Products and
                           Marker Panel Processes sold.

                  3.       Accounting for all Marker Panel Products and Marker
                           Panel Processes sold.

                  4.       Applicable deductions.

                  5.       Total royalties due.

                  6.       Names and addresses of all Sublicensees of Licensee.

                  7.       Payments received by Licensee from Affiliates and
                           Sublicensees.

                  8.       Marker Panel Products manufactured and sold to the
                           U.S. Government. No royalty obligations shall arise
                           from sales or use by, for or on behalf of the U.S.
                           Government in view of a royalty-free, nonexclusive
                           license that may heretofore have been granted to the
                           U.S. Government.

                  9.       Consideration (e.g. Royalties and Fees) received
                           from Sublicensees.

         D.       Until the First Commercial Sale of a Marker Panel Product or
Marker Panel Process, Licensee shall provide to CMCC at least annually
reasonable detail regarding the activities of Licensee and Licensee's
Affiliates and Sublicensees relative to achieving the objectives set forth in
the Development Plan in a timely manner, including but not limited to, reports
of financial expenditures to achieve said objectives, research and development
activities, regulatory approvals, strategic alliances and manufacturing,
sublicensing and marketing efforts.

         E.       With each such report submitted, Licensee shall pay to CMCC
the royalties due and payable under this Agreement. If no royalties shall be
due, Licensee shall so report.

         F.       On or before the ninetieth (90th) day following the close of
Licensee's fiscal year, Licensee shall provide CMCC with Licensee's certified
financial statements for the preceding fiscal year, including at a minimum a
balance sheet and an operating statement.

                         ARTICLE VI. PATENT PROSECUTION

         A.       CMCC shall apply for, seek prompt issuance of, and maintain
during the term of this Agreement the Patent Rights set forth in Appendix 3. The
prosecution, filing and maintenance of all Patent Rights applications and
patents shall be the primary responsibility of CMCC. Licensee shall have
reasonable opportunities to advise CMCC, including the selection of counsel,
and shall cooperate with CMCC in the prosecution, filing and maintenance of the
Patent Rights.

         B.       Licensee shall reimburse to CMCC the amount of all fees and
costs relating to the filing, prosecution and maintenance of the Patent Rights
incurred after the date of this Agreement. CMCC shall provide to Licensee an
itemized invoice of all such fees and Licensee

                                      11
<PAGE>   14

shall pay to CMCC all amounts due under said invoice within ten (10) days of
the date of said invoice. If the Patent Rights are licensed to third parties
for other fields of use, such patent costs shall be equitably apportioned.

         C.       In the event CMCC elects not to pursue, maintain or retain a
particular Patent Right licensed to Licensee hereunder, CMCC shall so notify
Licensee in sufficient time for Licensee to assume the filing, prosecution
and/or maintenance of such application or patent at Licensee's expense. In such
event, CMCC shall provide to Licensee any authorization necessary to permit
Licensee to pursue and/or maintain such Patent Right. Licensee shall have no
further royalty obligations under this Agreement with respect to any such
Patent Right.

                           ARTICLE VII. INFRINGEMENT

         A.       Licensee and CMCC shall each inform the other promptly in
writing of any alleged infringement by a third party of the Patent Rights in
the Field of Use and of any available evidence thereof.

         B.       During the term of this Agreement, CMCC shall have the right,
but shall not be obligated, to prosecute at its own expense any infringement of
the Patent Rights and, in furtherance of such right, Licensee hereby agrees
that CMCC may include Licensee as a party plaintiff in any such suit, without
expense to Licensee and shall keep Licensee informed as to the status of such
suit. The total cost of any such infringement action commenced or defended
solely by CMCC shall be borne by CMCC. CMCC shall keep any recovery or damages
for past infringement derived therefrom except that CMCC shall pay Licensee the
equivalent amount as if royalties were calculated on Net Sales by Licensee.
CMCC shall indemnify Licensee against any order for costs that may be made
against Licensee in such proceedings.

         C.       If within six (6) months after having been notified of any
alleged infringement, CMCC shall have been unsuccessful in persuading the
alleged infringer to desist and shall not have brought and shall not be
diligently prosecuting an infringement action, or if CMCC shall notify Licensee
at any time prior thereto of its intention not to bring suit against any
alleged infringer then, and in those events only, Licensee shall have the
right, but shall not be obligated, to prosecute at its own expense any
infringement of the Patent Rights, and Licensee may, for such purposes, use the
name of CMCC as party plaintiff; provided, however, that such right to bring
such an infringement action shall remain in effect only for so long as the
license granted hereunder remains exclusive. No settlement, consent judgment or
other voluntary final disposition of the suit may be entered into without the
consent of CMCC, which consent shall not be unreasonably withheld. Licensee
shall indemnify CMCC against any order for costs that may be made against CMCC
in such proceedings.

         D.       In the event Licensee shall undertake the enforcement and/or
defense of the Patent Rights by litigation, Licensee may withhold up to fifty
percent (50%) of the payments otherwise thereafter due to CMCC under Article IV
above and apply the same toward reimbursement of up to fifty percent (50%) of
Licensee's expenses, including reasonable attorney's fees, in connection
therewith. Any recovery of damages by Licensee for each such suit shall be
applied first in satisfaction of any unreimbursed expenses and legal fees of
Licensee relating to such suit and next toward reimbursement of CMCC for any
payments under Article IV past due or withheld and applied pursuant to this
Article VII. Licensee shall

                                      12
<PAGE>   15

keep any remaining balance except that Licensee shall pay CMCC the equivalent
amount as if royalties were calculated on Net Sales by Licensee.

         E.       In the event that a declaratory judgment action alleging
invalidity or noninfringement of any of the Patent Rights shall be brought
against Licensee, CMCC, at its option, shall have the right, within thirty (30)
days after commencement of such action, to intervene and participate in the
defense of the action at its own expense.

         F.       In any infringement suit which either party may institute to
enforce the Patent Rights pursuant to this Agreement, the other party hereto
shall, at the request and the expense of the party initiating such suit,
cooperate in all reasonable respects and, to the extent reasonably possible,
have its employees testify when requested and make available relevant records,
papers, information, samples, specimens, and the like.

         G.       Licensee shall during the exclusive period of this Agreement
have the sole right subject to the terms and conditions hereof to sublicense
any alleged infringer for future use of the Patent Rights. Any upfront fees
paid to Licensee as part of such a sublicense shall be Sublicense
Consideration.

                     ARTICLE VIII. UNIFORM INDEMNIFICATION
                            AND INSURANCE PROVISIONS

         A.       Licensee shall indemnify, defend and hold harmless CMCC, its
corporate affiliates, current or future directors, trustees, officers, faculty,
medical and professional staff, employees, students and agents and their
respective successors, heirs and assigns (the "Indemnitees"), against any
liability, damage, loss or expense (including reasonable attorney's fees and
expenses of litigation) incurred by or imposed upon the Indemnitees or any one
of them in connection with any claims, suits, actions, demands or judgments
arising out of any theory of product liability (including, but not limited to,
actions in the form of tort, warranty, or strict liability) concerning any
product, process or service made, used or sold by Licensee or any Sublicensee
pursuant to any right or license granted to Licensee under this Agreement.

         B.       Licensee agrees, at its own expense, to provide attorneys
reasonably acceptable to CMCC to defend against any actions brought or filed
against any party indemnified by Licensee hereunder with respect to the subject
of indemnity contained herein, whether or not such actions are rightfully
brought.

         C.       Licensee's indemnification under Article VIII, Paragraph A
and duty to defend under Article VIII, Paragraph B above shall not apply to any
liability, damage, loss or expense to the extent that it is directly
attributable to the negligent activities, reckless misconduct or intentional
misconduct of the Indemnitees.

         D.       Beginning at the time as any product, process or service
relating to, or developed pursuant to, this Agreement is being commercially
distributed or sold (other than for the purpose of obtaining regulatory
approvals) by Licensee or by a Sublicensee, Affiliate or agent of Licensee,
Licensee shall, at its sole cost and expense, procure and maintain policies of
commercial general liability and products liability insurance in amounts not
less than $2,000,000 per incident and $2,000,000 annual aggregate and naming
the Indemnitees as additional

                                      13
<PAGE>   16

insureds. Such commercial general liability insurance shall provide (i) product
liability coverage and (ii) contractual liability coverage for Licensee's
indemnification under Article VIII, Paragraphs A through C of this Agreement.
If Licensee elects to self-insure all or part of the limits described above
(including deductibles or retentions which are in excess of $250,000 annual
aggregate), such self-insurance program must be acceptable to CMCC and the Risk
Management Foundation of the Harvard Medical Institutions, Inc. The minimum
amount of insurance coverage required under this Article VIII, Paragraph D.
shall not be construed to create a limit of Licensee's liability with respect
to its indemnification under Article VIII, Paragraphs A through C of this
Agreement.

         E.       Licensee shall provide CMCC with written evidence of such
insurance upon request of CMCC. Licensee shall provide CMCC with written notice
at least thirty (30) days prior to the cancellation, non-renewal or material
change in such insurance. If Licensee does not obtain replacement insurance
providing comparable coverage within such thirty (30) day period, CMCC shall
have the right to terminate this Agreement effective at the end of such thirty
(30) day period without notice of any additional waiting periods. In such an
event, Licensee shall have thirty (30) days to reinstate this Agreement by
providing written evidence of replacement insurance providing comparable
coverage.

         F.       Licensee shall maintain such commercial general liability
insurance during (i) the period that any such product, process or service is
being commercially distributed or sold (other than for the purpose of obtaining
regulatory approvals) by Licensee or by a Sublicensee, Affiliate or agent of
Licensee and (ii) a reasonable period after the period referred to above, which
in no event shall be less than fifteen (15) years unless tail insurance that
affords equivalent coverage is obtained.

         H.       Children's represents and warrants that: (i) it has the right
and ability to grant the license set forth in Article II herein and (ii) that
the execution and delivery of this Agreement and the grant of the licenses to
Licensee hereunder do not conflict with the rights of any third party under any
other agreement to which CMCC is a party.

         I.       OTHER THAN WARRANTIES SET FORTH HEREIN, CMCC MAKES NO
WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR
PURPOSE WITH RESPECT TO ANY PATENT, TRADEMARK, SOFTWARE, TRADE SECRET, TANGIBLE
RESEARCH PROPERTY, INFORMATION OR DATA LICENSED OR OTHERWISE PROVIDED TO
LICENSEE HEREUNDER AND HEREBY DISCLAIMS THE SAME.

         J.       Article VIII, Paragraphs A through I shall survive expiration
or termination of this Agreement.

                          ARTICLE IX. EXPORT CONTROLS

         It is understood that CMCC is subject to United States laws and
regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities (including the Arms Export Control
Act, as amended and the Export Administration Act of 1979), and that its
obligations hereunder are contingent on compliance with applicable United
States

                                      14
<PAGE>   17

export laws and regulations. The transfer of certain technical data and
commodities may require a license from the cognizant agency of the United
States Government and/or written assurances by Licensee that Licensee shall not
export data or commodities to certain foreign countries without prior approval
of such agency. CMCC neither represents that a license shall not be required,
nor that if required, it shall be issued.

                          ARTICLE X. NON-USE OF NAMES

         Licensee shall not use the name of Children's Medical Center
Corporation nor the name of any of its corporate affiliates or employees, nor
any adaptation thereof, in any advertising, promotional or sales literature
without prior written consent obtained from CMCC in each case, which consent
shall not be unreasonably withheld. CMCC shall respond, in writing, to any
request within five (5) business days. Notwithstanding the foregoing
restrictions, Licensee may state that it is licensed by CMCC under one or more
of the patents and/or applications comprising the Patent Rights, and Licensee
may comply with disclosure requirements, as reasonably interpreted by its
counsel, of all applicable laws and regulations relating to its business,
including United States and state security laws.

                             ARTICLE XI. ASSIGNMENT

         A.       Except as otherwise provided herein, this Agreement is not
assignable in whole or in part, and any attempt to do so shall be void and of
no effect.

         B.       CMCC may assign this Agreement at any time to any corporate
affiliate of CMCC without the prior consent of Licensee.

         C.       Except as provided in Article XI, Paragraph D below, Licensee
may assign this Agreement to another entity only with the prior written consent
of CMCC, which consent shall not be unreasonably withheld or delayed.

         D.       Notwithstanding anything herein to the contrary, in the event
Licensee merges with another entity, is acquired by another entity, or sells
all or substantially all of its assets to another entity, Licensee may assign
its rights and obligations hereunder to, in the event of a merger or
acquisition, the surviving entity, and in the event of a sale, the acquiring
entity, without CMCC's consent so long as: (i) Licensee is not then in breach
of this Agreement; (ii) the proposed assignee has a net worth at least
equivalent to the net worth Licensee had as of the date of this Agreement;
(iii) the proposed assignee has available resources and sufficient scientific,
business and other expertise comparable to Licensee in order to satisfy its
obligations hereunder; (iv) Licensee provides written notice of the assignment
to CMCC, together with documentation sufficient to demonstrate the requirements
set forth in subparagraphs (i) through (iii) above, at least thirty (30) days
prior to the effective date of the assignment; and (v) CMCC receives from the
assignee, in writing, at least thirty (30) days prior to the effective date of
the assignment: (a) reaffirmation of the terms of this Agreement; (b) an
agreement to be bound by the terms of this Agreement; and (c) an agreement to
perform the obligations of Licensee under this Agreement.

                                      15
<PAGE>   18
                ARTICLE XII. DISPUTE RESOLUTION AND ARBITRATION

         A.       Except for the right of either party to apply to a court of
competent jurisdiction for a temporary restraining order, a preliminary
injunction, or other equitable relief to preserve the status quo or prevent
irreparable harm, any and all claims, disputes or controversies arising under,
out of, or in connection with the Agreement, including any dispute relating to
patent validity or infringement, which the parties shall be unable to resolve
within sixty (60) days shall be mediated in good faith. The party raising such
dispute shall promptly advise the other of such claim, dispute or controversy
in writing, describing the dispute in reasonable detail. By no later than five
(5) business says after the recipient has received such notice of dispute, each
party shall have selected a representative who shall have the authority to bind
such party and shall have advised the other party in writing of the name and
title of such representative.

         B.       Within fifteen (15) days of receipt of a request for
mediation as described above, the parties agree to commence mediation in the
City of Boston, Commonwealth of Massachusetts in accordance with the policies
and procedures of Endispute, Inc. ("Endispute"), or in the event that Endispute
is no longer in operation, in accordance with the policies and procedures of
the American Arbitration Association (the "AAA"). The parties shall select a
mediator acceptable to both of them from a list provided by Endispute. The
parties agree to cooperate in good faith in said mediator's efforts to assist
the parties to resolve the dispute. Each party agrees to pay fifty percent
(50%) of the costs of said mediation. If the matter has not been resolved
within thirty (30) days of the commencement of mediation, either party may
request in writing that the matter be submitted to arbitration in accordance
with the following subparagraph.

         C.       Any and all claims, disputes or controversies arising under,
out of, or in connection with this Agreement, which have not been resolved by
good faith negotiations between the parties or by mediation shall be resolved
by final and binding arbitration in Boston, Massachusetts, in accordance with
the rules of the AAA then obtaining and all expenses, in connection therewith,
will be shared equally, except for the expense of the parties' respective legal
counsels. A single arbitrator shall be mutually agreed upon and if the parties
are unable to agree on a mutually acceptable arbitrator, an arbitrator shall be
chosen in accordance with AAA rules. Any award rendered in such arbitration
shall be final and may be enforced by either party.

         D.       Notwithstanding the foregoing, nothing in this Article shall
be construed to waive any rights or timely performance of any obligations
existing under this Agreement.

                       ARTICLE XIII. TERM AND TERMINATION

         A.       The term of this Agreement shall be not less than fifteen
(15) years or the life of the last expiring Patent Right, whichever period is
the longer term.

         B.       CMCC may terminate this Agreement immediately upon the
bankruptcy, insolvency, liquidation, dissolution or cessation of operations of
Licensee; or the filing of any voluntary petition for bankruptcy, dissolution,
liquidation or winding-up of the affairs of Licensee; or any assignment by
Licensee for the benefit of creditors; or the filing of any involuntary
petition for bankruptcy, dissolution, liquidation or winding-up of the affairs
of Licensee which is not dismissed within ninety (90) days of the date on which
it is filed or commenced.

                                      16
<PAGE>   19

         C.       CMCC may terminate this Agreement upon thirty (30) days prior
written notice in the event of Licensee's failure to pay to CMCC royalties due
and payable hereunder in a timely manner, unless Licensee shall make all such
payments to CMCC within said thirty (30) day period. Upon the expiration of the
thirty (30) day period, if Licensee shall not have made all such payments to
CMCC, the rights, privileges and licenses granted hereunder shall terminate.

         D.       Except as otherwise provided in Paragraph C above, either
party may terminate this Agreement upon sixty (60) days prior written notice in
the event of the other party's breach or default of any material term or
condition or warranty contained in this Agreement, unless breaching party shall
cure such breach to the nonbreaching party's reasonable satisfaction within
said sixty (60) day period. Upon the expiration of the sixty (60) day period,
if the breaching party shall not have cured said breach to the reasonable
satisfaction of the nonbreaching party, the rights, privileges and license
granted hereunder shall terminate.

         E.       Licensee shall have the right to terminate this Agreement at
any time upon six (6) months' prior written notice to CMCC, and upon payment by
Licensee of all amounts due CMCC through the effective date of termination.

         F.       Upon termination of this Agreement for any reason, nothing
herein shall be construed to release either party from any obligation that
matured prior to the effective date of such termination. Licensee and any
Sublicensee thereof may, however, after the effective date of such termination,
sell all Marker Panel Products and complete Marker Panel Products in the
process of manufacture at the time of such termination and sell the same,
provided that Licensee shall pay to CMCC the royalties thereon as required
under this Agreement and shall submit the reports required under this Agreement
on the sales of Marker Panel Products.

            ARTICLE XIV. PAYMENTS, NOTICES, AND OTHER COMMUNICATIONS

         A.       All payments, notices, reports and/or other communications
made in accordance with this Agreement, shall be sufficiently made or given on
the date of the mailing if delivered by hand, by facsimile or sent by first
class mail postage prepaid and addressed as follows:

         In the case of CMCC:

                  Director, Intellectual Property Office
                  Children's Hospital
                  300 Longwood Avenue
                  Boston, MA  02115

         In the case of Licensee:

                  Bart Chernow, M.D. President
                  GMP|Diagnostic|Prognostic Markers
                  One East Broward Boulevard, Suite 1701
                  Fort Lauderdale, FL 33301

or such other address as either party shall notify the other in writing.

                                      17
<PAGE>   20

                         ARTICLE XV. GENERAL PROVISIONS

         A.       All rights and remedies hereunder will be cumulative and not
alternative.

         B.       This Agreement may be amended only by written agreement
signed by the parties.

         C.       It is expressly agreed by the parties hereto that CMCC and
Licensee are independent contractors and nothing in this Agreement is intended
to create an employer relationship, joint venture, or partnership between the
parties. No party has the authority to bind the other.

         D.       This Agreement constitutes the entire agreement between the
parties with respect to the subject matter hereof and supersedes all proposals,
negotiations and other communications between the parties, whether written or
oral, with respect to the subject matter hereof.

         E.       If any provisions of this Agreement shall be held to be
invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions of this Agreement shall not be impaired thereby.

         F.       CMCC agrees to promptly issue, from time to time, upon
written request, estoppel certificates in favor of the Licensee, Sublicensees
or potential Sublicensees setting forth the status of this Agreement and, if in
default, the conditions required to cure the same.

         G.       This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original as against the party whose signature
appears thereon, but all of which taken together shall constitute but one and
the same instrument.

         H.       The failure of either party to assert a right to which it is
entitled or to insist upon compliance with any term or condition of this
Agreement shall not constitute a waiver of that right or excuse a similar
subsequent failure to perform any such term or condition by the other party.

         I.       Licensee agrees to mark any Marker Panel Products sold in the
United States with all applicable United States patent numbers. All Marker
Panel Products shipped to or sold in other countries shall be marked in such a
manner as to conform with the patent laws and practices of the country of
manufacture or sale.

         J.       Each party hereto agrees to execute, acknowledge and deliver
such further instruments and do all such further acts as may be necessary or
appropriate to carry out the purposes and intent of this Agreement.

         K.       The paragraph headings contained in this Agreement are for
reference purposes only and shall not in any way affect the meaning or
interpretation of this Agreement.

         L.       This Agreement shall be governed by the laws of the
Commonwealth of Massachusetts, without regard to conflict of law rules.

                                      18
<PAGE>   21

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date last written below.

CHILDREN'S MEDICAL CENTER          LICENSEE
CORPORATION

By:                                By:
   ---------------------------        -----------------------------------------

Name:  William New                 Name: Jeffrey L. Raney

Title: VP of Research              Title: Secretary, GMP|Diagnostic|Prognostics
       Administration                     Markers, Inc.

Date: May 25, 2000                 Date: May 25, 2000

                                      19
<PAGE>   22

                                   APPENDIX 1

Patent Rights for the Burnham License Agreement

<TABLE>
             <S>                                            <C>
             ---------------------------------------------- -----------------------------------------------
              Patent Family                                 U.S. Patent Nos., Application Nos. or
                                                            Application Names
             ---------------------------------------------- -----------------------------------------------
             1.  BAP-1 Family                               i.   5,539,094
             ---------------------------------------------- -----------------------------------------------
                                                            ii.  5,650,491
             ---------------------------------------------- -----------------------------------------------
                                                            iii. 5,641,866
             ---------------------------------------------- -----------------------------------------------
                                                            iv.  5,686,595
             ---------------------------------------------- -----------------------------------------------
             2.  BCL-G Family                               i.  Patent application(1) filed 12/14/99
             ---------------------------------------------- -----------------------------------------------
             3.  BAG Family                                 i.  Patent application filed 9/9/98 (5 novel
                                                            genes)
             ---------------------------------------------- -----------------------------------------------
                                                            ii. Patent application filed 7/9/99 (method
                                                            claims)
             ---------------------------------------------- -----------------------------------------------
             4.  BAX Inhibitor Protein                      i.   5,837,838
             ---------------------------------------------- -----------------------------------------------
             5. Traf Family                                 Novel Traf Family Proteins
             ---------------------------------------------- -----------------------------------------------
</TABLE>

---------
(1)  Application Serial Nos. not available

                                      20
<PAGE>   23

                                   APPENDIX 2

Patent Rights for the Moses License Agreement

         6,037,138 (breast cancer associated MMP)
         09/469,637 (urine assay, etc.)

                                      21
<PAGE>   24

                                   APPENDIX 3

Patent Rights for the Zetter License Agreement

         5,663,071 (nucleic acids, vectors, host cell)
         5,721,337 (protein)
         5,831,033 (antibody)
         CMCC 737 (TB 16)
         5,858,681 (method of prognosis)
         09/135,599 (method of diagnosis)
         6,017,717
         PCT/US98/21671
         ID CMCC 737

                                      22
<PAGE>   25
*** CONFIDENTIAL INFORMATION OMITTED AND FILED SEPARATELY WITH THE SECURITIES
    AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                   APPENDIX 4

                                DEVELOPMENT PLAN

         GMP|Diagnostic|Prognostic Markers, Inc. agrees to fund up to an
aggregate of [***] to fund the research and development and the
commercialization of the Marker Panel Products and Marker Panel Processes, and
shall attempt to develop a Marker Panel Product or Marker Panel Process pursuant
to the following schedule:

June 1, 2000 through May 31, 2003 - GMP agrees to fund or cause third parties
to timely fund the Sponsored Research Agreement at [***] per year for three
years.

Third quarter 2003 - Start clinical trials, if necessary, for FDA approval.

June 1, 2003 through May 31, 2005 - Obtain FDA approval and develop boxed
assays in commercial form.

                                      23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]